These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 27118646)

  • 41. A SUV
    Ye L; Xu F; Shi S; Zeng Z; Jin X; Huang Y; Lu C; Gu J; Ge D; He J
    Clin Transl Oncol; 2018 Aug; 20(8):1026-1034. PubMed ID: 29327241
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
    Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
    Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prognostic value of PET/CT in lung cancer: retrospective analysis of 47 patients].
    de Guevara DL; Fuentes A; Fariña C; Corral C; Pefaur R
    Rev Med Chil; 2013 Jan; 141(1):41-8. PubMed ID: 23732413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy.
    Imamura Y; Azuma K; Kurata S; Hattori S; Sasada T; Kinoshita T; Okamoto M; Kawayama T; Kaida H; Ishibashi M; Aizawa H
    Lung Cancer; 2011 Jan; 71(1):49-54. PubMed ID: 20430470
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
    Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
    Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
    Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic value of preoperative fluorodeoxyglucose positron emission tomography/computed tomography in patients with potentially resectable pancreatic cancer.
    Omiya Y; Ichikawa S; Satoh Y; Motosugi U; Nakajima N; Onishi H
    Abdom Radiol (NY); 2018 Dec; 43(12):3381-3389. PubMed ID: 30043215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
    Kwon W; Howard BA; Herndon JE; Patz EF
    J Thorac Oncol; 2015 Jun; 10(6):897-902. PubMed ID: 25811445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
    BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
    Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by
    Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
    J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 18F-fluorodeoxyglucose positron emission tomographic scan in solid-type p-stage-I pulmonary adenocarcinomas: what can produce false-negative results?
    Lococo F; Galeone C; Formisano D; Bellafiore S; Filice A; Annunziata T; Cesario A; Rapicetta C; Fioroni F; Ricchetti T; Paci M
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):667-673. PubMed ID: 28043987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of quantified metabolic activity in nonsmall cell lung cancer with tumor size and tumor pathological characteristics.
    Karam MB; Doroudinia A; Behzadi B; Mehrian P; Koma AY
    Medicine (Baltimore); 2018 Aug; 97(32):e11628. PubMed ID: 30095621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Correlation analysis between 18F-FDG uptake features and the prognosis in patients with pathologic stage Ⅰ lung adenocarcinoma].
    Liu Y; Wu N; Bi GC; Zhang DS; Zheng R; Liang Y; Zhang WJ; Li XM; Fang Y
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):263-9. PubMed ID: 27087372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R
    J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Large cell neuroendocrine carcinoma of the lung: CT and FDG PET findings.
    Lee KW; Lee Y; Oh SW; Jin KN; Goo JM
    Eur J Radiol; 2015 Nov; 84(11):2332-8. PubMed ID: 26279139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.